Galapagos Suffers Record Drop as FDA Fails to Approve Drug

Belgian biotech company Galapagos NV lost about a third of its market value — its biggest decline on record — after the U.S. Food and Drug Administration failed to approve a rheumatoid arthritis treatment it’s developing with partner Gilead Sciences Inc.